Xenetic Q3 Loss Widens to $1.7M as Santersus Deal Costs Hit G&A; Cash Falls to $5.8M
XBIO is trading near its 52-week low of $1.58 (5.1% above the low) on light trading volume (0.3× avg).
Summary
Xenetic's Q3 net loss widened to $1.70M from $0.51M as Santersus deal costs drove G&A up 138%, while royalty revenue fell 29.4% and cash dropped to $5.81M. The all-stock Santersus merger still awaits a stockholder vote.
Key Events · Earnings and Guidance · XBIO
-
Q3 Net Loss Widens Sharply
Net loss was $1.70M for the three months ended September 30, 2026, versus $0.51M a year earlier; nine-month net loss reached $3.08M versus $2.10M.
-
Deal Costs Drive G&A Up 138%
General and administrative expense rose to $1.94M in Q3 from $0.82M, attributed to legal and financial advisory services related to the Santersus Acquisition.
-
Royalty Revenue Falls 29.4%
Q3 revenue dropped to $0.73M from $1.03M on lower Takeda royalty revenue; nine-month revenue was roughly flat at $2.19M versus $2.21M.
-
Cash Falls to $5.8M
Cash was $5.81M at September 30, 2026, down from $7.88M at December 31, 2025; working capital fell to $4.1M from $7.1M. Management says resources fund operations for at least twelve months.
Analysis · XBIO · Life Sciences
Cost, not operations, is the quarter's headline: general and administrative expense more than doubled to $1.94M on legal and financial advisory work for the pending all-stock Santersus acquisition, pushing the net loss to $1.70M from $0.51M a year ago. Royalty revenue from the Takeda sublicense slipped 29.4% to $0.73M, so the company is burning cash while it waits on the deal. Cash fell to $5.81M from $7.88M at year-end, and management says existing resources cover at least twelve months — but the combined company will need substantial new capital, and the filing flags a possible reverse split to hold Nasdaq listing. The merger still needs a Xenetic stockholder vote, and Santersus holders are set to own roughly 85% of the combined company.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XBIO was trading at $1.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.9M. The 52-week trading range was $1.58 to $4.94. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.